Francinny Alves Kelly/X
Nov 14, 2026, 14:08
Francinny Alves Kelly: AHA Scientific Sessions 2026 Features Research on CHA₂DS₂-VASc and Transhepatic AF Ablation
Francinny Alves Kelly, Physician, Research Fellow at BIDMC CVI, shared a post on X:
“Proud to represent the BIDMC CVI EP group at Scientific Sessions 26 with two moderated poster presentations on CHA₂DS₂-VASc in the contemporary anticoagulation era and transhepatic access for AF ablation.
Grateful to Andre d’Avila and our coauthors for their support!”
Stay updated with Hemostasis Today.
-
Nov 14, 2026, 14:08Bruno Pougault: Lupus Anticoagulant Testing During DOAC Therapy
-
Nov 14, 2026, 14:03Newborn Vitamin K Prophylaxis and the Risk of Bleeding – JAMA
-
Nov 14, 2026, 14:03Denis Oduor: Shaping the Future of Transfusion Medicine at Terumo BCT Africa Hackathon 2026
-
Nov 14, 2026, 14:01Maria Elisa Mancuso: Shaping the Future of Hemophilia Care Together!
-
Nov 14, 2026, 13:58Deniz Aslan: Advancing Pediatric Beta-Thalassemia Screening
-
Nov 14, 2026, 13:56ASPERA-R Study Investigates Anticoagulation Timing Following Breakthrough Ischemic Stroke – International Journal of Stroke
-
Nov 14, 2026, 13:47Karen A. Moffat: New 2026 Issue on Laboratory Diagnostics in Thrombosis and Haemostasis
-
Nov 14, 2026, 13:45César Erazo: Investigating Anticoagulation in Secondary Stroke Prevention at AHA 2026
-
Nov 14, 2026, 13:41Hussein Abdelwahab: FDA Approves Asundexian as the First Factor XIa Inhibitor for Stroke Prevention